BBOT reports 65% ORR for BBO-8520, first panKRAS response in PDAC, no hyperglycemia with BBO-10203

BridgeBio Oncology Therapeutics, Inc.

BBO-8520 monotherapy: 65% ORR (11/17), 66% 6-month PFS, including one complete response; all 5 STK11/KEAP1 co-mutant patients achieved PR.
BBO-8520 + pembrolizumab: all 8 evaluable patients had tumor reduction; 3/3 front-line and 2/5 prior KRAS G12C inhibitor patients achieved PR.
BBO-11818 panKRAS inhibitor: first monotherapy PR in pancreatic ductal adenocarcinoma (44% tumor reduction); dose-proportional exposure covering G12D/G12V at 600 mg BID.
BBO-10203 RAS:PI3Kα breaker: no hyperglycemia of any grade, no baseline HbA1c/glucose restrictions; 500 mg QD selected for expansion; combination studies initiated.
Combination studies of BBO-8520, BBO-11818, and BBO-10203 with each other and with standard-of-care expected to open in H2 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.